Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price fell 5.5% on Monday . The stock traded as low as $69.2750 and last traded at $70.06. 628,948 shares were traded during trading, an increase of 232% from the average session volume of 189,291 shares. The stock had previously closed at $74.14.
Gemini Therapeutics Price Performance
The business has a 50-day moving average of $77.62 and a 200-day moving average of $70.91. The company has a market capitalization of $2.92 billion, a P/E ratio of -67.30 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics was a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company’s research centered primarily on ophthalmology, with an emphasis on therapies for retinal and complement-related disorders.
Its lead investigational product was GEM103, a recombinant form of human complement factor H. Gemini evaluated GEM103 as a potential treatment for geographic atrophy, an advanced form of dry age-related macular degeneration associated with degeneration of the retina.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- 5 Buy-and-Hold Stocks Built to Weather a Volatile Market
- Movado’s Turnaround Gains Momentum
- Qualcomm’s Discount Could Vanish If Its AI Bet Pays Off
- Micron’s AI Memory Boom Could Send Shares 100% Higher
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
